Generic pull and industry sales help keep the retail pharmacist in growth

Generic pull and industry sales help keep the retail pharmacist in generic drugs growth not only pulled the sales growth in the pharmaceutical industry in Brazil in the first half as they prevented the market retraction of medicines in the country. Survey of the Brazilian Association of generic drug Industries, the PróGenéricos, points out that sales of the segment grew 11.5% in 2014, the first six months compared to the same period in 2013. Were marketed 416.1 thousand units of category of medicines against 373.1 in the first half of last year.
In gross revenue, sales of generic drugs totaled R $ 7,5 billion reais in the first half of this year against 3 billion R$6,2 same period of the previous year, showing evolution of 18.31 percent.
Sales in the sector as a whole, including all other categories of medicinal products added to generic, showed growth of 7.8%, i.e. out of 1.381 billion between January and June 2013 and reached the mark of 1.489 billion units in the same period this year. In values, the total of Brazilian pharmaceutical retail sales in the first half totaled r $ 30.9 billion reais compared to r $ 27.3 billion in the same period in 2013, 13.26% growth.
The survey shows that when we exclude generics of the results of the national pharmaceutical market, the performance of sales in units was 6.8%. In values, without generics revenues from pharmaceutical industry sales would have presented slight shrinkage of 0.1%.
The PróGenéricos revised its expectation of growth for 2014. "We imagined grow 20% in units, however, we would be pleased if you capture a 15% growth in sales," said Telma Salles, Executive President of PróGenéricos. The authority States that a review on the tax system of medicines could reverse the stagnation scenario lived throughout the industry at the current time. "Generics would still cheaper," he says.
Salles also points out that the main attribute of generics, interchangeability, is critical to maintaining the achievements brought by generics and also to continue guaranteeing growth for the industries. "It's good for all sides, population, industry and Government, to assure the prerogative of generic interchangeability. Hasty changes can confuse consumers, undermine big companies change discounts policies that guarantee prices more accessible to generics, locking the purpose of Government is to ensure the expansion process to medicines, "donates concludes.